Advertisement


Erika P. Hamilton, MD, FASCO, on HER2-Positive Metastatic Breast Cancer: Maintenance Therapy Comparison

ASCO 2026

Advertisement

Erika P. Hamilton, MD, FASCO, of Sarah Cannon Research Institute, talks about a comparison of the efficacy and safety of tucatinib vs placebo combined with trastuzumab and pertuzumab as maintenance therapy for HER2-positive metastatic breast cancer by stratified subgroups (Abstract 1005).



Related Videos

Pancreatic Cancer

Brian M. Wolpin, MD, MPH, and Eileen M. O’Reilly, MD, on Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

Brian M. Wolpin, MD, MPH, of Dana-Farber Cancer Institute, and Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, describe results from the phase III RASolute 302 trial, which evaluated the RAS(ON) muliselective inhibitor daraxonrasib in previously treated patients with metastatic pancreatic adenocarcinoma (Abstract LBA5).

Lung Cancer
Pancreatic Cancer

Julie R. Gralow, MD, FACP, FASCO, on Highlights of the 2026 ASCO Annual Meeting

Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer and Executive Vice President of ASCO, provides an overview of the highlights of this year’s meeting, including practice-changing data included in the Plenary Session.

Lung Cancer

Tony S.K. Mok, MD, FRCPC, FASCO, on Advanced ALK-Positive NSCLC: 7-Year Update From the CROWN Trial

Tony S.K. Mok, MD, FRCPC, FASCO, of the Chinese University of Hong Kong, presents long-term findings from the CROWN trial, which evaluated lorlatinib vs crizotinib in patients with advanced ALK-positive non–small cell lung cancer (NSCLC). At 5 years, median progression-free survival was not reached with lorlatinib in this population, representing the longest progression-free survival ever reported in advanced NSCLC (Abstract 8502). 

Lung Cancer

John V. Heymach, MD, PhD, on First-Line Therapy for Advanced NSCLC With EGFR Exon 20 Insertions

John V. Heymach, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses results from the primary analysis of the multinational phase III WU-KONG28 trial, which looked at sunvozertinib monotherapy vs platinum-based therapy as first-line treatment for patients with advanced non–small cell lung cancer (NSCLC) and EGFR exon 20 insertions (Abstract LBA8500). 

Skin Cancer

Katharina C. Kaehler, MD, on Daromun in Resectable Locally Advanced Melanoma: Trial Updates

Katharina C. Kaehler, MD, of University Hospital (UKSH), Campus Kiel, presents an update on the primary outcome and sensitivity analyses from the PIVOTAL phase III trial of daromun, a combination of two fibronectin-targeting immunocytokines (L19IL2 and L19TNF), as a neoadjuvant intralesional therapy in patients with resectable, locally advanced stage III melanoma (Abstract LBA9517). 

Advertisement

Advertisement




Advertisement